In recent years, the immune checkpoint proteins such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) or the programmed cell death ligand 1/protein 1 pathway (PD-L1/PD-1) have been used as crucial targets for immunotherapy in many cancers, including LUAD [11, 12]. This evidence concerns the gene PDCD1 and cancer.